Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: michael modeme who wrote (457)	12/9/1999 8:37:00 PM
From: Casaubon	Read Replies (1) \| Respond to of 3044

I have 13 years of drug design experience. I know how the game is played. I have been on patents for drugs in the clinic which have failed and might even be on one that will succeed. Good Luck! PS If it succeeds, it might even make money.

To: michael modeme who wrote (457)	12/9/1999 11:46:00 PM
From: Casaubon	Read Replies (1) \| Respond to of 3044

Right now, (given enough money) I could, by myself, develop a gene chip assay for chrom 22 in humans, look at expression levels among different genotypes, and do statistical analyses for the correlation between gene regulation and diseases specific to the 22nd chrom. And I am just one person with limited experience By the way, what you have described here is a means of identifying a target protein, not a drug. This is, of course, what MLNM does. You still have to design a drug for your target. God, how many great targets I've seen crash and burn, because the drug entity was too insoluble, metabolically unstable, toxic, had poor pharmicodynamics, wasn't active enough, too much competion to market, too small a target population, and the list goes on. I almost never give advice, but here's something to really consider. Take some money off the table. Enjoy it. Don't look back 5 years from now and think how much more you could have had if you just held on. Good Luck!